The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury

Sean M Bagshaw, R T Noel Gibney, Finlay A McAlister, Rinaldo Bellomo, Sean M Bagshaw, R T Noel Gibney, Finlay A McAlister, Rinaldo Bellomo

Abstract

Background: Furosemide is commonly prescribed in critically ill patients with acute kidney injury (AKI). Existing data from observational studies and small clinical trials have significant limitations and have reported conflicting findings. There remains controversy on whether furosemide can impact clinical outcomes in critically ill patients with AKI; however, a survey of intensivists and nephrologists showed equipoise for high-quality evidence on this important issue.

Design/methods: This protocol summarizes the rationale and design of a phase II randomized, blinded, placebo-controlled trial of a low-dose continuous infusion of furosemide, titrated to the physiology parameter of urine output, in critically ill patients with early AKI. Two hundred sixteen adult critically ill patients with early evidence of AKI, defined by the RIFLE criteria, will be enrolled. Included patients will also have fulfilled >or=2 criteria of the systemic inflammatory response syndrome and achieved immediate goals of acute resuscitation. The primary outcome is progression in severity of kidney injury. Secondary outcomes include: safety, fluid balance, electrolyte balance, the need for renal replacement therapy, duration of AKI, rate of renal recovery, mortality and changes in novel serum and urine biomarkers of AKI. The primary analysis will be intention-to-treat. Planned recruitment will be complete by June 2011 and results available by December 2011.

Trial registration: ClinicalTrials.gov Identifier NCT00978354.

Figures

Figure 1
Figure 1
Overview of patient flow.
Figure 2
Figure 2
Overview of the SPARK study drug infusion algorithm.

References

    1. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18:1292–1298. doi: 10.1681/ASN.2006070756.
    1. Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care. 2007;11:R68. doi: 10.1186/cc5949.
    1. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006;17:1135–1142. doi: 10.1681/ASN.2005060668.
    1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–818. doi: 10.1001/jama.294.7.813.
    1. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, Godinez-Luna T, Svenson LW, Rosenal T. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care. 2005;9:R700–R709. doi: 10.1186/cc3879.
    1. Korkeila M, Ruokonen E, Takala J. Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med. 2000;26:1824–1831. doi: 10.1007/s001340000726.
    1. Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl. 1998;66:S16–24.
    1. Manns B, Doig CJ, Lee H, Dean S, Tonelli M, Johnson D, Donaldson C. Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med. 2003;31:449–455. doi: 10.1097/01.CCM.0000045182.90302.B3.
    1. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002;30:2051–2058. doi: 10.1097/00003246-200209000-00016.
    1. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. Jama. 2009;302:1179–1185. doi: 10.1001/jama.2009.1322.
    1. Hamel MB, Phillips RS, Davis RB, Desbiens N, Connors AF Jr, Teno JM, Wenger N, Lynn J, Wu AW, Fulkerson W, Tsevat J. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med. 1997;127:195–202.
    1. Kellum JA, Leblanc M, Gibney RTN, Tumlin J, Lieberthal W, Ronco C. Primary prevention of acute renal failure in the critically ill. Current Opinion in Critical Care. 2005;11(6):537–541.
    1. Abel RM, Beck CH Jr, Abbott WM, Ryan JA, Barnett GO Jr, Fischer JE. Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose. Results of a prospective, double-blind study. N Engl J Med. 1973;288:695–699.
    1. De Torrente A, Miller PD, Cronin RE, Paulsin PE, Erickson AL, Schrier RW. Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure. Am J Physiol. 1978;235:F131–136.
    1. Kramer HJ, Schuurmann J, Wassermann C, Dusing R. Prostaglandin-independent protection by furosemide from oliguric ischemic renal failure in conscious rats. Kidney Int. 1980;17:455–464. doi: 10.1038/ki.1980.53.
    1. Aravindan N, Aravindan S, Riedel BJ, Weng HR, Shaw AD. Furosemide prevents apoptosis and associated gene expression in a rat model of surgical ischemic acute renal failure. Ren Fail. 2007;29:399–407. doi: 10.1080/08860220701263671.
    1. Aravindan N, Shaw A. Effect of furosemide infusion on renal hemodynamics and angiogenesis gene expression in acute renal ischemia/reperfusion. Ren Fail. 2006;28:25–35. doi: 10.1080/08860220500461229.
    1. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427. doi: 10.1038/ki.2009.159.
    1. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74. doi: 10.1186/cc6916.
    1. Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R. Diuretics in the management of acute kidney injury: A multinational survey. Contrib Nephrol. 2007;156:236–249. full_text.
    1. Uchino S, Doig GS, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Nacedo E, Gibney N, Tolwani A, Ronco C, Kellum JA. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Diuretics and mortality in acute renal failure. Crit Care Med. 2004;32:1669–1677. doi: 10.1097/01.CCM.0000132892.51063.2F.
    1. Cantarovich F, Fernandez JC, Locatelli A, Perez Loredo J. Frusemide in high doses in the treatment of acute renal failure. Postgraduate Medical Journal. 1971;47(Suppl):13–17.
    1. Cantarovich F, Galli C, Benedetti L, Chena C, Castro L, Correa C, Perez Loredo J, Fernandez JC, Locatelli A, Tizado J. High dose frusemide in established acute renal failure. British Medical Journal. 1973;4:449–450. doi: 10.1136/bmj.4.5890.449.
    1. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004;44:402–409. doi: 10.1016/S0272-6386(04)00810-8.
    1. Chandra M, Agarwal SS, Mitra NK, Gupta NN. Massive intravenous frusemide therapy in acute renal failure. J Indian Med Assoc. 1975;64:47–48.
    1. Lucas CE, Zito JG, Carter KM, Cortez A, Stebner FC. Questionable value of furosemide in preventing renal failure. Surgery. 1977;82:341–320.
    1. Seedat YK. High dose frusemide in established acute renal failure. Br Med J. 1973;4:784. doi: 10.1136/bmj.4.5895.784-b.
    1. Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Annals of Thoracic Surgery. 2000;69:501–506. doi: 10.1016/S0003-4975(99)01298-9.
    1. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62:413–415. doi: 10.1159/000187090.
    1. Zito J, Cortez A, Lucas CE, Stebner FC, Rosenberg IK, Jaanimagi JL. Distribution of renal blood flow after furosemide in critically ill patients. Surg Forum. 1976;27:27–29.
    1. Mehta RL, Pascual MT, Soroko S, Chertow GM, Group PS. Diuretics, mortality, and nonrecovery of renal function in acute renal failure[see comment] JAMA. 2002;288:2547–2553. doi: 10.1001/jama.288.20.2547.
    1. Karayannopoulos S. High-dose frusemide in renal failure. Br Med J. 1974;2:278–279.
    1. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, J F. Furosemide in acute oliguric renal failure. A controlled trial. Nephron. 1976;17:51–58. doi: 10.1159/000180710.
    1. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrology Dialysis Transplantation. 1997;12:2592–2596. doi: 10.1093/ndt/12.12.2592.
    1. Vargas Hein O, Staegemann M, Wagner D, von Heymann C, Martin M, Morgera S, Spies C. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Renal Failure. 2005;27:385–392. doi: 10.1081/JDI-65298.
    1. Kellum JA. Diuretics in acute renal failure: protective or deleterious. Blood Purif. 1997;15:319–322. doi: 10.1159/000170350.
    1. Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? Jama. 2002;288:2599–2601. doi: 10.1001/jama.288.20.2599.
    1. Noble DW. Acute renal failure and diuretics: propensity, equipoise, and the need for a clinical trial. Critical Care Medicine. 2004;32:1794–1795. doi: 10.1097/01.CCM.0000134836.50831.73.
    1. Schetz M. Should we use diuretics in acute renal failure? Best Pract Res Clin Anaesthesiol. 2004;18:75–89. doi: 10.1016/j.bpa.2003.09.003.
    1. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. Bmj. 2006.
    1. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc. 2007;9:68. doi: 10.1186/cc5949.
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–212. doi: 10.1186/cc2872.
    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655. doi: 10.1378/chest.101.6.1644.
    1. Ostermann M, Alvarez G, Sharpe MD, Martin CM. Frusemide administration in critically ill patients by continuous compared to bolus therapy. Nephron Clin Pract. 2007;107:c70–76. doi: 10.1159/000108641.
    1. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650–655.
    1. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73. doi: 10.1186/cc4915.
    1. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–439. doi: 10.2215/CJN.03681106.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren